Preliminary Evaluation of a Novel Lupus Anticoagulant Activity Assay Unaffected by Anticoagulants
Journal of Clinical Laboratory Analysis · 2026-08 · 40 (15)
DOI: 10.1002/jcla.70292 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Laboratory Analysis, online erschienen am 17.06.2026. Verfasst von Ayu Hidaka und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Science, Faculty of Health Science, Yamaguchi University Graduate School of Medicine, Ube, Japan. Hauptthemen laut MEDLINE: Lupus Coagulation Inhibitor, Anticoagulants. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Background
In Japan, clinical laboratories commonly assess lupus anticoagulant (LA) activity using phospholipid‐dependent coagulation assays as part of the diagnostic evaluation of antiphospholipid syndrome (APS). However, LA detection involves complex procedures and may yield false‐positive results in patients receiving anticoagulant therapy, such as direct oral anticoagulants (DOACs). This study aimed to clarify the effects of anticoagulants on guideline‐based LA testing (diluted Russell's viper venom time (dRVVT) and/or LA‐sensitive activated partial thromboplastin time (APTT)) and to evaluate whether they interfere with accurate LA assessment. We also explore a simple one‐step method to minimize anticoagulant interference and improve diagnostic efficiency.
Methods
We developed a one‐step method for assessing LA activity by calculating the LA‐sensitivity ratio (LA‐SR), defined as the ratio of APTT measured using high‐ and low‐sensitivity APTT reagents. The clinical utility of the LA‐SR assay was evaluated using plasma samples from 57 patients with systemic lupus erythematosus, 74 patients with prolonged APTT, and DOAC‐spiked plasmas.
Results
The method showed agreement with the guideline‐based LA testing. Of the 57 cases, 14 were LA‐positive and 38 were LA‐negative according to guideline‐based testing. Among the 43 cases classified as LA‐negative, five showed elevated LA‐SR values despite negative guideline‐based results. The LA‐SR assay was minimally affected by DOACs, warfarin, heparin, or coagulation factor deficiencies.
Conclusion
This LA‐SR‐based method may serve as a useful screening tool for the evaluation of LA activity. A negative LA‐SR result may help identify samples unlikely to have LA activity, while positive results should be interpreted cautiously and confirmed using guideline‐based testing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Science, Faculty of Health Science, Yamaguchi University Graduate School of Medicine, Ube, Japan.
ORCID-Profile: Risa Kaneshige
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Hidaka, A., Kaneshige, R., Nakamura, S., Motoki, Y., & Nojima, J. (2026). Preliminary Evaluation of a Novel Lupus Anticoagulant Activity Assay Unaffected by Anticoagulants. Journal of Clinical Laboratory Analysis, 40(15). https://doi.org/10.1002/jcla.70292
Vancouver
Hidaka A, Kaneshige R, Nakamura S, Motoki Y, Nojima J. Preliminary Evaluation of a Novel Lupus Anticoagulant Activity Assay Unaffected by Anticoagulants. Journal of Clinical Laboratory Analysis. 2026;40(15). doi:10.1002/jcla.70292
BibTeX
@article{Hidaka2026,
author = {Hidaka, Ayu and Kaneshige, Risa and Nakamura, Seika and Motoki, Yukari and Nojima, Junzo},
title = {Preliminary Evaluation of a Novel Lupus Anticoagulant Activity Assay Unaffected by Anticoagulants},
journal = {Journal of Clinical Laboratory Analysis},
year = {2026},
volume = {40},
number = {15},
doi = {10.1002/jcla.70292}
}
EUVIMED